# Gene Therapy: Vectors, Strategies, and Clinical Milestones

## Introduction

Gene therapy aims to treat or cure disease by introducing, altering, or replacing genetic material within a patient's cells. After decades of preclinical development and early setbacks, the field has achieved landmark clinical successes with multiple FDA-approved gene therapies now available for inherited diseases. Understanding vector biology, delivery strategies, and the current clinical landscape is essential for medical geneticists.

## Gene Therapy Strategies

### Gene Addition (Augmentation)

Gene addition involves delivery of a functional copy of a gene to compensate for a loss-of-function variant. The therapeutic transgene operates independently without correcting the endogenous mutation. This is the most common strategy for recessive disorders where a single functional copy restores adequate protein production. Examples include RPE65 gene therapy for Leber congenital amaurosis and SMN1 delivery for spinal muscular atrophy.

### Gene Silencing

Gene silencing reduces or eliminates expression of a toxic gain-of-function gene product. Approaches include RNA interference (shRNA/siRNA delivered via viral vector) and antisense oligonucleotides. This strategy is applicable to dominant-negative conditions and trinucleotide repeat disorders where the disease mechanism involves a toxic protein rather than protein deficiency.

### Gene Editing

Gene editing involves precise correction or disruption of the endogenous gene using programmable nucleases such as CRISPR-Cas9, base editors, and prime editors. This approach offers the potential for definitive correction at the DNA level.

### Gene Regulation

Gene regulation modulates expression of an endogenous gene without altering its sequence. An important example is reactivating fetal hemoglobin (HBG1/2) to compensate for sickle cell disease or beta-thalassemia, exploiting a developmental gene switch rather than correcting the disease-causing mutation directly.

![Diagram illustrating the four major gene therapy strategies: gene addition, gene silencing, gene editing, and gene regulation with examples](images/gene-therapy-strategies.png)

## Viral Vectors

### Adeno-Associated Virus (AAV)

AAV is the most widely used vector for in vivo gene therapy. It is a small, non-enveloped, single-stranded DNA virus not known to cause human disease. Multiple serotypes (AAV1-9, AAVrh10, and others) provide different tissue tropisms: AAV9 crosses the blood-brain barrier for CNS and systemic delivery, AAV8 has liver tropism, AAV1 and AAV6 target skeletal muscle, and AAV2 is used for retinal delivery via subretinal injection. The transgene exists predominantly as episomes with low integration risk. The packaging capacity of approximately 4.7 kb limits its use for large genes such as full-length dystrophin at 11.5 kb. Pre-existing neutralizing antibodies against common AAV serotypes are present in approximately 30-60% of humans, which can prevent transduction. Capsid-directed immune responses can cause liver toxicity, making immunosuppression protocols standard in AAV-based therapies.

### Lentiviral Vectors (LV)

Lentiviral vectors are derived from HIV-1 but engineered for safety as self-inactivating, replication-incompetent constructs. As integrating vectors, they stably insert the transgene into the host genome, which is critical for dividing cells such as hematopoietic stem cells. Their packaging capacity of approximately 8-10 kb accommodates larger transgenes than AAV. They are used primarily for ex vivo gene therapy of hematopoietic stem cells. Modern lentiviral vectors have a favorable integration profile with no clinically observed insertional oncogenesis, in contrast to earlier gamma-retroviral vectors.

### Gamma-Retroviral Vectors

Gamma-retroviral vectors were used in early gene therapy and integrate into the host genome. However, insertional mutagenesis proved a significant safety concern: in SCID-X1 trials, integration near the LMO2 oncogene caused T-cell leukemia in 5 of 20 patients. They have been largely replaced by lentiviral vectors with improved safety profiles.

### Adenoviral Vectors

Adenoviral vectors offer high transduction efficiency but strong immunogenicity. The Jesse Gelsinger case in 1999, involving a fatal immune reaction in an ornithine transcarbamylase deficiency trial, was a watershed event in gene therapy regulation. Adenoviral vectors are now used primarily in vaccines rather than gene therapy for genetic diseases.

| Vector | Packaging Capacity | Integration | Tropism | Immunogenicity | Key Clinical Use |
|---|---|---|---|---|---|
| AAV | ~4.7 kb | Episomal (low integration) | Serotype-dependent (liver, CNS, muscle, retina) | Moderate (pre-existing Abs in 30–60%) | In vivo gene addition (SMA, hemophilia, LCA) |
| Lentiviral | ~8–10 kb | Integrating (stable) | Broad (pseudotyped) | Low | Ex vivo HSC gene therapy (SCD, beta-thal, ALD) |
| Gamma-retroviral | ~8 kb | Integrating (near promoters) | Dividing cells | Low | Historical; replaced by lentiviral due to insertional oncogenesis |
| Adenoviral | ~36 kb | Non-integrating | Broad | High | Vaccines; limited gene therapy use |
| LNP (non-viral) | No strict limit (mRNA/DNA) | Non-integrating | Liver (GalNAc); systemic | Minimal | mRNA delivery; CRISPR delivery |

## Non-Viral Delivery

Lipid nanoparticles (LNPs) are used to deliver mRNA or CRISPR components and have been successfully employed in mRNA vaccines and are being adapted for gene therapy. Electroporation is a physical method for introducing genetic material into cells ex vivo. Non-viral approaches offer advantages including no pre-existing immunity, no insertional mutagenesis risk, and easier manufacturing. Their limitations include generally lower efficiency and shorter duration of expression compared to viral vectors.

![Comparison table of viral vector properties including packaging capacity, integration behavior, tropism, immunogenicity, and clinical applications](images/gene-therapy-vectors-comparison.png)

## Delivery Routes

### In Vivo Delivery

In vivo delivery administers the therapeutic vector directly to the patient. Intravenous administration provides systemic distribution and is used for liver-targeted therapies such as hemophilia treatments and CNS-targeted therapies such as SMA treatment. Subretinal or intravitreal injection delivers vector directly to retinal cells. Intrathecal or intracisternal routes deliver to the CSF for CNS disorders. Intramuscular injection provides local muscle transduction for conditions such as Duchenne muscular dystrophy.

### Ex Vivo Delivery

In ex vivo delivery, patient cells are harvested, genetically modified in the laboratory, and reinfused. This approach is used primarily for hematopoietic stem cell gene therapy and requires myeloablative or reduced-intensity conditioning to create space for the modified cells. Examples include gene therapy for sickle cell disease, beta-thalassemia, SCID, and cerebral adrenoleukodystrophy.

## FDA-Approved Gene Therapies (Select Milestones)

### Voretigene Neparvovec (Luxturna, 2017)

Luxturna was the first FDA-approved gene therapy for an inherited disease. It uses an AAV2 vector to deliver RPE65 for biallelic RPE65-associated retinal dystrophy. Administered via subretinal injection, it demonstrated improved visual function in the pivotal trial.

### Onasemnogene Abeparvovec (Zolgensma, 2019)

Zolgensma uses an AAV9 vector to deliver SMN1 for spinal muscular atrophy type 1. A single intravenous dose produces dramatic improvement in motor function and survival. It is one of the most expensive therapies at approximately $2.1 million per dose.

### Betibeglogene Autotemcel (Zynteglo, 2022)

Zynteglo uses lentiviral vector-modified autologous hematopoietic stem cells for transfusion-dependent beta-thalassemia. The majority of treated patients achieve transfusion independence.

### Exa-cel (Casgevy, 2023)

Casgevy uses CRISPR/Cas9-edited autologous hematopoietic stem cells for sickle cell disease and transfusion-dependent beta-thalassemia. It was the first CRISPR-based therapy approved.

### Lovotibeglogene Autotemcel (Lyfgenia, 2023)

Lyfgenia is a lentiviral HSC gene therapy for sickle cell disease that reduces vaso-occlusive crises. Concerns about insertional oncogenesis remain under monitoring.

### Delandistrogene Moxeparvovec (Elevidys, 2023)

Elevidys is an AAV-based micro-dystrophin gene therapy for Duchenne muscular dystrophy that received accelerated approval with ongoing confirmatory studies.

## Safety Considerations

Hepatotoxicity from AAV-mediated gene therapy can be triggered by immune-mediated liver injury in a dose-dependent manner, and corticosteroid protocols are standard. Thrombotic microangiopathy (TMA) from complement activation has been observed with high-dose AAV, with fatal cases reported in DMD trials. Dorsal root ganglion (DRG) toxicity involving sensory neuron degeneration has been observed in animal studies and some human trials with intrathecal AAV. Insertional oncogenesis remains primarily a concern with integrating vectors, requiring long-term monitoring for lentiviral therapies. Durability of expression is a concern because AAV episomes may be diluted in dividing cells, particularly in pediatric patients, and re-dosing is complicated by anti-AAV immunity.

![Timeline of major gene therapy clinical milestones from the first human trial through FDA approvals showing key successes and setbacks](images/gene-therapy-milestones-timeline.png)

## Clinical Pearls

AAV vectors are the dominant platform for in vivo gene therapy, but their limited packaging capacity, pre-existing immunity in many patients, and dose-dependent toxicity are significant challenges that constrain their application. Ex vivo lentiviral gene therapy of hematopoietic stem cells has proven effective for hemoglobinopathies, immunodeficiencies, and metabolic storage diseases. The cost of gene therapies, ranging from $1-3 million per treatment, creates access challenges and demands novel payment models including value-based and outcomes-based pricing. Long-term follow-up studies are essential because the durability of gene therapy effects and late-onset safety signals remain active areas of investigation requiring vigilance over years to decades.

## References

1. Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age. *Science*. 2018;359(6372):eaan4672.
2. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *New England Journal of Medicine*. 2017;377(18):1713-1722.
3. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy. *Lancet*. 2017;390(10097):849-860.
4. High KA, Roncarolo MG. Gene therapy. *New England Journal of Medicine*. 2019;381(5):455-464.